Table 3.

Change and % change of VAS, ODI, and RDQ from baseline.

	Change			% Change
Week	PRPr	CS	p-Value	PRPr	CS	p-Value
VAS
4	−19.0 ± 21.3	−34.9 ± 20.1	0.15	−29.4 ± 37.0	−57.6 ± 31.2	0.13
8	−30.9 ± 22.7	−26.3 ± 29.8	0.73	−48.2 ± 34.9	−41.7 ± 54.5	0.78
12 (4)	−38.3 ± 19.6	−32.8 ± 13.4	0.56	−60.1 ± 31.9	−56.4 ± 22.0	0.81
16 (8)	−47.9 ± 21.2	−33.3 ± 13.4	0.18	−74.2 ± 33.5	−57.3 ± 22.5	0.30
20 (12)	−45.4 ± 26.3	−29.8 ± 12.8	0.64	−67.5 ± 37.3	−68.7 ± 20.3	0.94
32 (26)	−56.8 ± 20.2	−36.8 ± 17.1	0.10	−84.2 ± 23.8	−66.6 ± 28.6	0.25
60 (52)	−53.4 ± 24.7	−36.4 ± 23.7	0.25	−78.2 ± 33.2	−61.0 ± 37.9	0.41
ODI (%)
4	−8.2 ± 9.5	−7.2 ± 8.4	0.83	−20.4 ± 27.1	−28.5 ± 38.0	0.63
8	−14.5 ± 11.6	−7.7 ± 8.9	0.22	−37.7 ± 31.9	−31.0 ± 41.1	0.72
12 (4)	−17.9 ± 13.2	−11.2 ± 7.8	0.30	−46.5 ± 33.4	−37.1 ± 34.4	0.61
16 (8)	−23.6 ± 14.9	−11.9 ± 7.3	0.10	−62.1 ± 30.6	−39.0 ± 32.2	0.19
20 (12)	−21.9 ± 13.4	−12.7 ± 6.1	0.14	−58.9 ± 31.1	−43.4 ± 32.1	0.37
32 (26)	−26.9 ± 13.1	−14.5 ± 10.8	0.14	−74.8 ± 27.9	−45.9 ± 41.1	0.18
60 (52)	−26.6 ± 14.8	−13.9 ± 9.7	0.12	−76.0 ± 37.6	−42.4 ± 31.5	0.13
RDQ
4	−2.2 ± 5.9	−2.3 ± 4.2	0.95	−25.6 ± 97.1	−38.0 ± 58.4	0.27
8	−3.4 ± 6.7	−1.7 ± 4.2	0.58	−39.5 ± 85.8	−32.8 ± 58.5	0.54
12 (4)	−6.9 ± 6.4	−1.6 ± 3.6	0.13	−54.8 ± 67.5	−31.0 ± 47.8	0.51
16 (8)	−6.6 ± 6.1	−1.7 ± 2.9	0.10	−56.7 ± 63.7	−25.6 ± 43.2	0.32
20 (12)	−6.7 ± 6.2	−2.3 ± 4.6	0.17	−65.7 ± 35.4	−32.8 ± 56.1	0.18
32 (26)	−8.5 ± 5.3	−3.4 ± 4.0	0.09	−88.0 ± 23.5	−42.1 ± 45.1	0.03 *
60 (52)	−8.8 ± 5.0	−4.2 ± 4.5	0.13	−92.8 ± 14.1	−49.6 ± 44.4	0.10

Change (time points − baseline) and % change ([time points − baseline]/baseline × 100) in visual analog scale (VAS), Oswestry Disability Index (ODI) [26], and Roland-Morris Disability Questionnaire (RDQ) [27,28] until 60 weeks after the injection of the platelet-rich plasma releasate (PRPr) or corticosteroid (CS). Number in parentheses indicates weeks after the optional injection. Data were expressed as means ± standard deviation (SD). * p < 0.05 between the groups.